{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129417","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.726608+00:00","generated_at":"2026-05-29T02:30:53.763732+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Assertio appoints Schwichtenberg as CTO, Pietryga as CCO, Reisenauer to board","bullets":["Paul Schwichtenberg (formerly CCO, CFO) named Chief Transformation Officer effective Dec 16, 2024, focusing on growth and new revenue strategies.","Mary Pietryga appointed Chief Commercial Officer effective Dec 16, 2024, overseeing sales, marketing, and access.","Mark Reisenauer, former President US Commercial at Astellas, appointed to board effective Jan 2, 2025, also joining Compensation Committee.","Pietryga joins from Teva Pharmaceuticals as VP and Head of Global Biosimilar Portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129417","json":"https://secwatch.observer/filing/0001104659-24-129417.json","markdown":"https://secwatch.observer/filing/0001104659-24-129417.md","text":"https://secwatch.observer/filing/0001104659-24-129417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000110465924129417/0001104659-24-129417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000110465924129417/tm2430960d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:30:53.763732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}